A promising ingredient brief often reaches procurement as a single phrase: “source an orotate.” That is too broad for a useful commercial response. A development team may need the parent orotic acid, a specified metal salt, or a defined lithium research material; each choice creates a different identity, documentation and pricing conversation. Nanchang Polis Biotech Co., Ltd. lists seven entries in its orotic acid derivatives category. The practical opportunity for B2B buyers is to turn that range into a precise inquiry, then assess each offered material against its own specification and intended market. Buyer takeaway Start with the exact product form and intended use; ask for a matching specification and sample before discussing volume pricing. The portfolio is a useful starting point, but the seven listings are separate sourcing decisions. Illustrative image. Product identity and commercial specifications must be confirmed from the current technical documents. Seven listings, three starting questions A product team can narrow the discussion quickly by asking: Do we need orotic acid itself, a specific metal ion, or a research-stage lithium salt? The table follows the current English category page. Its CAS entries reproduce the site's listings rather than certifying the identity of any particular delivered lot. Listed productListed CASFirst point to clarify Orotic acid65-86-1Ask for the exact form and specification shown on the offered lot. Orotic acid anhydrous65-86-1State whether anhydrous form is essential to the process. Potassium orotate24598-73-0Specify the potassium salt and the analytical basis required. Magnesium orotate34717-03-8Confirm the salt form, hydration state and relevant test methods. Zinc orotate68399-76-8Define the zinc-content and impurity data your project needs. Calcium orotate22454-86-0State the calcium-salt identity and market-specific documents. Lithium orotate / orotic acid lithium salt monohydrate5266-20-6Define research purpose and applicable market restrictions before requesting a quote. The official category currently displays CAS 65-86-1 for both “Orotic acid” and “Orotic acid anhydrous.” Do not infer the hydration state of the first listing from its name alone. Confirm the offered material's name, formula, water content and specification with Polis Biotech before qualification. “Magnesium” is the standardized spelling used here for the site's “Magenesium” listing. Build the commercial brief around the decision A useful supplier introduction should make the next exchange faster. Separate the project into the following three decisions rather than sending a general request for “orotic acid derivatives.” 01 · Material identityName one SKU or a clearly marked shortlist. Give the target CAS, ion and hydrate state where known. If the development brief is still open, ask for separate specifications for the candidate forms; do not ask for one blended “orotate” quote. 02 · Qualification evidenceDescribe the intended industrial or research use, destination country and required test limits. Request a current specification, representative certificate of analysis and safety data sheet for the exact offered form; agree which methods and reporting basis will be used in the buyer's evaluation. 03 · Commercial scaleProvide the sample quantity, expected first order, annual forecast, destination and preferred packing. Ask for quoted lead time, trade terms and any documentation needed for the destination market. These are questions for a quotation, not promises of stock, capacity or a fixed delivery time. Illustrative image. Confirm current availability, packing and shipment terms in the quotation. A ready-to-send inquiry for Polis Biotech The most helpful first message is short enough for the sales team to route, but specific enough for technical review. Replace the brackets below with the actual project requirements. Subject: Inquiry — [exact orotic acid / orotate product] for [destination market] We are evaluating [exact product and CAS] for [intended application]. Please provide the current specification, a representative COA, SDS and any documentation available for our destination market. Our target requirements are [assay / water / relevant elemental content / impurity or other test limits], with [method or reporting basis] where applicable. We seek [sample quantity] for evaluation, followed by [initial order quantity] and an estimated annual demand of [forecast]. Please advise available packing, indicative lead time, trade terms and the information needed to prepare a comparable quotation. If the listed name and CAS do not fully define the offered hydrate or salt form, please confirm the exact identity in the technical documents. Polis Biotech describes itself as a Nanchang-based manufacturer and supplier of amino acids and derivatives and publishes a custom synthesis service. Those company statements provide a reason to open a technical-commercial conversation; the suitability, availability and compliance of any particular orotate lot remain subject to direct confirmation. Frequently asked questions 1. How should a buyer distinguish Polis Biotech's Orotic acid from Orotic acid anhydrous?Polis Biotech lists Orotic acid and Orotic acid anhydrous separately while displaying CAS 65-86-1 for both. Ask for the offered form's specification, formula, water result and COA before treating them as equivalent or different in a purchasing system. 2. What should a Potassium orotate inquiry include?A Potassium orotate inquiry should identify the listed CAS 24598-73-0, intended use, destination market and the buyer's test requirements. Request documents for the exact offered Potassium orotate form rather than assuming another orotate salt's specification applies. 3. Can Magnesium orotate, Zinc orotate and Calcium orotate share one approval file?Magnesium orotate, Zinc orotate and Calcium orotate are separate listed materials with different metal ions and CAS entries. A buyer should qualify each against its own identity, specification, analytical data and intended market. 4. What information is useful before sampling Zinc orotate?For Zinc orotate, state the target application, zinc-content reporting basis, relevant impurity limits and sample quantity. The current Zinc orotate product page lists CAS 68399-76-8; a representative COA and specification should define the offered material in more detail. 5. How should a buyer discuss Lithium orotate / orotic acid lithium salt monohydrate?For Lithium orotate / orotic acid lithium salt monohydrate, identify CAS 5266-20-6, the research or industrial purpose and destination-market requirements. A supplier listing does not establish authorization for a medical or consumer use, and this article makes no therapeutic claim. 6. When should a project team contact Polis Biotech about Orotic acid derivatives?Contact Polis Biotech about Orotic acid derivatives once the team can name a target material or shortlist, expected testing, destination and indicative quantity. If the identity remains open, explicitly ask for distinct specifications for the forms being considered. Start a specific supplier conversation Send your exact product name, intended market, test targets and sample-to-order plan to Nanchang Polis Biotech Co., Ltd. Email: sales@polisbiotech.com · Tel: +86-791-88172690 · Mobile: +86-13870623110 · View the Orotic acid derivatives range Sources and verification: Polis Biotech product category; company profile; custom synthesis page; and the individual product pages linked in the table. All product identities and CAS entries are reported as displayed on the official site at the time of writing. Technical and regulatory suitability must be verified with current primary documentation for the actual lot and destination. Author statement: Prepared as a B2B editorial guide for Nanchang Polis Biotech Co., Ltd. on 30 October 2026. The two images are illustrative concepts, not evidence of the company's facilities, inventory or specific commercial lots. No medical efficacy, regulatory approval, stock level or delivery promise is implied. Tags: Orotic Acid Derivatives · Orotic Acid · Potassium Orotate · Magnesium Orotate · Zinc Orotate · Calcium Orotate · Lithium Orotate · B2B Chemical Sourcing {"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://www.polisbiotech.com/#organization","name":"Nanchang Polis Biotech Co., Ltd.","url":"https://www.polisbiotech.com/","email":"sales@polisbiotech.com","telephone":"+86-791-88172690"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.polisbiotech.com/"},{"@type":"ListItem","position":2,"name":"News","item":"https://www.polisbiotech.com/news_en.html"},{"@type":"ListItem","position":3,"name":"From Lab Brief to Commercial Quote: Sourcing Orotic Acid Derivatives Across Seven SKUs"}]},{"@type":"BlogPosting","headline":"From Lab Brief to Commercial Quote: Sourcing Orotic Acid Derivatives Across Seven SKUs","description":"Explore Polis Biotech's seven listed orotic acid derivatives and turn a formulation concept into a clear sample, specification and commercial inquiry.","datePublished":"2026-10-30","inLanguage":"en","author":{"@id":"https://www.polisbiotech.com/#organization"},"publisher":{"@id":"https://www.polisbiotech.com/#organization"},"about":{"@type":"Thing","name":"Orotic acid derivatives"}},{"@type":"FAQPage","mainEntity":[{"@type":"Question","name":"How should a buyer distinguish Polis Biotech's Orotic acid from Orotic acid anhydrous?","acceptedAnswer":{"@type":"Answer","text":"Polis Biotech lists Orotic acid and Orotic acid anhydrous separately while displaying CAS 65-86-1 for both. Ask for the offered form's specification, formula, water result and COA before treating them as equivalent or different in a purchasing system."}},{"@type":"Question","name":"What should a Potassium orotate inquiry include?","acceptedAnswer":{"@type":"Answer","text":"A Potassium orotate inquiry should identify the listed CAS 24598-73-0, intended use, destination market and test requirements. Request documents for the exact offered Potassium orotate form."}},{"@type":"Question","name":"Can Magnesium orotate, Zinc orotate and Calcium orotate share one approval file?","acceptedAnswer":{"@type":"Answer","text":"Magnesium orotate, Zinc orotate and Calcium orotate are separate listed materials with different metal ions and CAS entries. Qualify each against its own identity, specification, analytical data and intended market."}},{"@type":"Question","name":"What information is useful before sampling Zinc orotate?","acceptedAnswer":{"@type":"Answer","text":"For Zinc orotate, state the target application, zinc-content reporting basis, relevant impurity limits and sample quantity. The current product page lists CAS 68399-76-8; a representative COA and specification should define the offered material in more detail."}},{"@type":"Question","name":"How should a buyer discuss Lithium orotate / orotic acid lithium salt monohydrate?","acceptedAnswer":{"@type":"Answer","text":"For Lithium orotate / orotic acid lithium salt monohydrate, identify CAS 5266-20-6, the research or industrial purpose and destination-market requirements. A supplier listing does not establish authorization for a medical or consumer use."}},{"@type":"Question","name":"When should a project team contact Polis Biotech about Orotic acid derivatives?","acceptedAnswer":{"@type":"Answer","text":"Contact Polis Biotech about Orotic acid derivatives once the team can name a target material or shortlist, expected testing, destination and indicative quantity. If identity remains open, request distinct specifications for the forms being considered."}}]}]}

Conclusion first: orotic acid is scientifically interesting because it sits at the intersection of pyrimidine biochemistry, heterocyclic chemistry and metal-salt formulation. Its derivatives should not be understood as one uniform “orotate” ingredient family. The parent acid, its monohydrate/anhydrous forms and its potassium, magnesium, zinc, calcium and lithium salts differ in stoichiometry, hydration, elemental loading, solubility and—most importantly—the strength of evidence supporting specific biological claims. That makes this category a good example of why modern ingredient science needs two disciplines at the same time: chemistry tells us what the material is; evidence tells us what we can responsibly say about it. Nanchang Polis Biotech Co., Ltd. currently groups seven related products in its Orotic Acid Derivatives portfolio, providing a useful framework for understanding the family. Orotic Acid Is an Intermediate in Pyrimidine Biosynthesis—not “Vitamin B13” in the Modern Nutritional Sense Orotic acid has historically been called “vitamin B13,” but it is not considered an essential vitamin. In human biochemistry, it is an intermediate in the de novo pathway that constructs pyrimidine nucleotides. The pathway builds the pyrimidine ring, produces orotate, attaches a phosphoribosyl group to form OMP and then decarboxylates OMP to UMP. UMP is the first pyrimidine nucleotide in the pathway and feeds the synthesis of other pyrimidine nucleotides needed for RNA, DNA and cellular metabolism. This is not a new hypothesis. Human orotic-acid biosynthesis was experimentally characterized decades ago, and modern reviews continue to place orotate at the center of de novo pyrimidine metabolism. A 2015 review also emphasized that orotic acid has biological roles beyond being a passive intermediate, while cautioning that its metabolic effects depend strongly on context and dose. Simple explanation: orotic acid is best viewed as a biochemical “junction molecule.” It is made on the way to pyrimidine nucleotides, but chemists can also isolate it, use its carboxyl group to make salts, or modify the heterocyclic scaffold to create derivatives. How Orotic Acid Is Made: Biology and Industrial Chemistry Take Different Routes Biological route In cells, carbamoyl phosphate and aspartate are converted through carbamoyl aspartate and dihydroorotate to orotate. Dihydroorotate dehydrogenase performs the oxidation step that produces orotic acid. Orotate is then converted through OMP to UMP. Chemical synthesis Industrial chemistry does not have to copy the cellular pathway. Literature and patents describe several synthetic approaches. One active Chinese patent, CN111499582B, describes a route beginning with urea and maleic anhydride to form a maleuric/maleyl-urea intermediate, followed by controlled oxidative/bromide chemistry, alkaline treatment, acidification, crystallization and drying to obtain orotic acid. Other laboratory methods use different pyrimidine-ring-building strategies. Important: the synthesis example above is cited to explain known chemistry. It does not state or imply that Polis Biotech or any specific manufacturing partner uses this exact process. Why Orotic Acid Monohydrate and Anhydrous Orotic Acid Need Separate Specifications NIST identifies anhydrous orotic acid as CAS 65-86-1 and notes 50887-69-9 as a hydrate; TCI identifies 50887-69-9 specifically as orotic acid monohydrate. Crystal water may look like a small detail, but it changes formula mass and can alter mass-based assay and drying behavior. Polis therefore lists Orotic Acid Monohydrate and Orotic Acid Anhydrous as separate products. R&D teams should preserve that distinction in specifications, reference standards, raw-material calculations and stability work. What Changes When Orotic Acid Becomes a Mineral Orotate? Orotic acid contains a carboxylic-acid group. Deprotonation allows the orotate anion to form salts with metal cations. This sounds simple, but the cation charge changes stoichiometry. A monovalent cation such as K⁺ can pair differently from a divalent cation such as Ca²⁺, Mg²⁺ or Zn²⁺. Crystal water can further change the formula mass. Elemental mineral fraction (%) = (atomic mass × number of mineral atoms in the defined formula ÷ molecular weight of the defined salt) × 100 That equation explains why “500 mg of an orotate” does not mean “500 mg of mineral.” For example, Polis publishes Potassium Orotate as C₅H₃N₂O₄K, MW 194.19, whereas Calcium Orotate is published as C₁₀H₆CaN₄O₈, MW 350.25. Different salts therefore require different elemental calculations. Product Scientific / Formulation Question Evidence Caution Product Link Orotic Acid Monohydrate Crystal water, drying and assay basis Do not compare directly with anhydrous material without correcting identity. View Orotic Acid Anhydrous Parent pyrimidine acid without crystal water Biological pathway relevance does not automatically establish a health benefit from supplementation. View Potassium Orotate Monovalent potassium salt; elemental K calculation Do not infer a unique therapeutic effect from the orotate ligand alone. View Magnesium Orotate Mg salt form, hydrate state, elemental Mg and dissolution Clinical literature exists, but results depend on indication, formulation and study design. View Zinc Orotate Zinc delivery, dissolution and pharmacokinetics Older animal pharmacokinetic data show distinct behavior, not a universal superiority claim. View Calcium Orotate Elemental calcium fraction and formulation Recent calcium guidance describes calcium-orotate absorption as not well studied. View Lithium Orotate Monohydrate Low-conductivity organic lithium salt; active research topic 2025 Nature results are preclinical and do not establish approved human AD treatment. View Different Orotate Salts Do Not Have One Shared “Bioavailability Advantage” This is where scientific discipline matters. Marketing language often assumes that attaching a mineral to orotate automatically produces superior absorption or intracellular delivery. The evidence does not support such a blanket conclusion. An older rabbit study comparing zinc sulfate, zinc pantothenate and zinc orotate found that zinc orotate showed different pharmacokinetic behavior, including slower oral absorption than the soluble salts. A recent calcium consensus statement notes that calcium orotate is relatively low in elemental calcium and that its bioavailability is not well studied. By contrast, magnesium orotate has a larger clinical literature, including cardiovascular studies and more recent research in combination interventions—but that evidence cannot simply be transferred to calcium, zinc or lithium orotate. Scientific rule: the shared orotate ligand is a chemical relationship, not proof of a shared clinical effect. Each salt needs its own evidence base. Lithium Orotate Is the Most Visible Emerging Research Signal—But the Evidence Boundary Matters A 2025 Nature study brought renewed attention to Lithium Orotate Monohydrate. The researchers found that endogenous lithium was reduced in brain tissue in mild cognitive impairment and Alzheimer's disease, and that amyloid could sequester lithium. In mouse models, lithium orotate showed lower amyloid binding than lithium carbonate and prevented or reversed several pathological and memory-related changes at low lithium exposure. This is scientifically important, but the correct 2026 interpretation is still preclinical research signal. The study does not establish that lithium orotate is an approved preventive or treatment for Alzheimer's disease in humans, nor does it establish a consumer dose. Responsible technical content should preserve that boundary. Where Magnesium, Zinc and Calcium Orotate Research Differs Magnesium Orotate has been studied clinically for several indications, and a 2024 randomized controlled trial evaluated a combination containing magnesium orotate, probiotics and CoQ10 in major depressive disorder. Because it was a multi-component intervention, the study cannot isolate the effect of magnesium orotate alone. Older cardiovascular literature is broader, but formulation, dose and indication still matter. Zinc Orotate has older pharmacokinetic research showing that its dissolution and absorption profile differs from soluble zinc salts. That is useful for formulation science but not evidence for universal superiority. Calcium Orotate is chemically well defined, but a 2026 calcium-supplement consensus statement describes its absorption as not well studied and its elemental-calcium content as relatively low compared with calcium carbonate. This is a useful example of why chemical novelty and clinical evidence should not be confused. How Formulation Scientists Should Choose Among Orotate Salts Start with the required ionChoose potassium, magnesium, zinc, calcium or lithium because the formulation requires that ion—not because “orotate” is assumed to confer one universal effect. Calculate elemental loadingUse the exact molecular formula and hydrate state. Finished-product dose calculations should be based on elemental mineral where relevant. Check solubility and processingSalt form can change dissolution, pH response, granulation, tablet size and suspension behavior. Match evidence to claimsResearch on one orotate salt, one species or one indication should not be transferred to another product without evidence. FAQ: Chemistry, Formulation and Research Questions 1. What is orotic acid biologically? Orotic acid is a normal intermediate in de novo pyrimidine nucleotide biosynthesis. It is converted to orotidine monophosphate and then UMP, which feeds the broader pyrimidine nucleotide pool. It is not correctly described as an essential vitamin. 2. What is the chemical difference between orotic acid monohydrate and anhydrous orotic acid? The orotic-acid molecule is the same core compound, but the monohydrate contains one stoichiometric water molecule in the crystal. This changes formula mass, water content and mass-based assay interpretation, so the two forms require separate specifications. 3. Are all orotate salts more bioavailable than conventional mineral salts? That general claim is not supported. Different orotate salts have different evidence bases. A recent calcium consensus statement, for example, describes calcium-orotate absorption as not well studied, while older zinc-orotate pharmacokinetic work found behavior that differed from soluble zinc salts. Each salt should be evaluated on its own evidence. 4. Why is lithium orotate receiving renewed research attention? A 2025 Nature study reported that lithium orotate showed reduced amyloid binding and prevented or reversed pathological changes in Alzheimer’s mouse models at low lithium exposure. This is important preclinical research, but it does not establish lithium orotate as an approved treatment for Alzheimer’s disease in humans. 5. How are orotate salts generally prepared? At a chemical level, the carboxylic-acid function of orotic acid can form salts with suitable metal bases or salts under controlled conditions, followed by crystallization and drying. Exact manufacturing routes, hydrate states and purification steps vary by product and producer. 6. Why should formulation scientists care about stoichiometry and hydration? Because the counter-ion charge and crystal water change molecular weight, elemental-mineral fraction, solubility and processing behavior. A formulation should be calculated using the defined commercial salt—not the mass of 'orotate' as a generic category. Sources & Verification Notes NCBI / pyrimidine metabolism. Orotic acid is an intermediate in de novo pyrimidine nucleotide synthesis and is converted through OMP to UMP. Pathway review Löffler, Carrey & Zameitat, 2015. Review: “Orotic Acid, More Than Just an Intermediate of Pyrimidine de novo Synthesis.” PubMed CN111499582B. Example of a modern patented chemical synthesis route to orotic acid; cited for chemistry context only. Google Patents Aron et al., Nature 2025. “Lithium deficiency and the onset of Alzheimer’s disease.” Preclinical mouse-model evidence for lithium orotate; not an approved human-treatment claim. Nature article Andermann & Dietz, 1982. Comparative pharmacokinetics of zinc pantothenate, zinc sulfate and zinc orotate in rabbits. PubMed Endocrine Society of India Skeletal Health Taskforce, 2026. Calcium-supplement consensus statement noting limited data for calcium orotate. Consensus statement Polis Biotech public product pages. Used for the current seven-product portfolio and company-published identities/specifications. Discuss an Orotic Acid or Orotate Development Project For a useful technical discussion, specify the required salt or hydrate, destination market, intended use, analytical target, sample quantity and expected commercial scale. This makes it easier to align chemistry, documentation and sourcing from the beginning. Nanchang Polis Biotech Co., Ltd. Email: sales@polisbiotech.com Tel: +86-791-88172690 · Mobile / WeChat: +86-13870623110 Web: www.polisbiotech.com

Conclusion first: buying orotic acid or an orotate salt in 2026 should begin with identity control, analytical comparability and supply repeatability—not with the lowest quoted price. The category looks simple on a purchasing list, but it contains different hydration states and different metal salts. A buyer who treats them as one commodity can create avoidable problems in specification matching, elemental calculations, regulatory review and downstream formulation. Nanchang Polis Biotech Co., Ltd. supplies a seven-product orotic-acid family covering orotic acid forms and mineral orotate salts. For international sourcing teams, the practical advantage of a broad portfolio is not that every product is interchangeable; it is that procurement can discuss several related forms with one technical-commercial interface and compare the right grade before sampling. 2026 Procurement Rule #1: Confirm the Exact Chemical Form Before Comparing Price The most important sourcing issue in this category is deceptively basic: “orotic acid” can refer to different hydration states. NIST lists CAS 65-86-1 for anhydrous orotic acid and notes 50887-69-9 as the hydrate. Tokyo Chemical Industry separately identifies 50887-69-9 as orotic acid monohydrate. That distinction matters because water of crystallization changes formula mass and the interpretation of assay on a mass basis. Buyer takeaway: the first comparison table in an RFQ should contain product name, hydration state, CAS, molecular formula, molecular weight, assay basis and test method. If one of these fields is inconsistent, pause the quotation comparison until identity is clarified. Polis currently lists both Orotic Acid (the hydrated form associated with CAS 50887-69-9) and Orotic Acid Anhydrous (CAS 65-86-1). For procurement, having both forms visible is useful only when the buyer treats them as separate SKUs with separate specifications. All Seven Products Should Be Qualified as Separate Materials Product Published / Reference Identity Why Buyers Should Treat It Separately Product Link Orotic Acid Monohydrate CAS 50887-69-9 Hydration changes molecular weight, assay basis and drying behavior. View product Orotic Acid Anhydrous CAS 65-86-1 Anhydrous identity should be confirmed independently from the hydrate. View product Potassium Orotate CAS 24598-73-0 Monovalent cation changes molecular weight, elemental loading and formulation behavior. View product Magnesium Orotate Orotic acid magnesium salt Divalent salt chemistry and hydrate state must be defined by the commercial specification. View product Zinc Orotate CAS 68399-76-8 Elemental zinc loading, water and impurity profile require their own limits. View product Calcium Orotate CAS 22454-86-0 Calcium content and exact salt form matter more than the shared “orotate” name. View product Lithium Orotate Monohydrate CAS 5266-20-6 Research interest has increased, but regulatory and application claims require extra caution. View product These seven products are also grouped in the Orotic Acid Derivatives portfolio. From a sourcing perspective, portfolio breadth is useful when it reduces search and communication cost, but every salt still needs a dedicated specification and approval file. What “Reliable Supply” Should Mean to a B2B Buyer Reliability is measurable. It should mean that the same agreed specification can be reproduced, tested with a stable analytical method and delivered with traceable documentation. A supplier relationship becomes stronger when purchasing, QC and R&D use the same definition of “same material.” Identity controlCorrect name, CAS, hydrate state, formula and specification must agree. This is especially important for anhydrous vs monohydrate orotic acid. Analytical comparabilityAssay, water, elemental content and impurities are only useful when the test method and reporting basis are understood. Multi-lot consistencyA buyer should review several lots where possible. One excellent sample is not evidence of routine commercial consistency. Change controlRaw-material source, production site or major analytical-method changes should be communicated when they can affect an approved specification. Polis's public Custom Synthesis page states that analytical support can include HPLC, GC, MS, ¹H/¹³C-NMR, IR, UV-Vis, elemental analysis and X-ray diffraction, with supply quantities ranging from grams and kilograms to tons. For buyers, the significance is not that every routine lot requires every technique; it is that the sourcing discussion can be matched to the analytical question instead of relying only on a generic COA. COA Review: Move From “Pass / Fail” to “Is the Method Fit for Purpose?” A COA is often treated as the end of quality evaluation. In specialty ingredients it should be the beginning. An assay value without method context can hide differences in sample drying, titration basis, chromatographic calculation or hydrate correction. The same is true for elemental content in mineral orotates. Elemental fraction (%) = (atomic mass of the mineral × stoichiometric count ÷ molecular weight of the defined salt) × 100 For example, Polis publishes potassium orotate as C₅H₃N₂O₄K with molecular weight 194.19. Calcium orotate is published as C₁₀H₆CaN₄O₈ with molecular weight 350.25. The elemental percentages are therefore inherently different, even before considering water or specification tolerances. This is why purchasing by “kg of salt” and purchasing by “kg of elemental mineral” are not the same commercial calculation. 2026 Sourcing Trend: Documentation Is Part of the Product Global ingredient sourcing is increasingly document-heavy. The same orotate can face different classification, labeling or permitted-use rules depending on whether it enters pharmaceutical R&D, a food supplement, a research reagent or another finished product. FDA's substance database, for example, identifies orotic acid as a substance but explicitly notes that a UNII does not mean regulatory approval. This is an important distinction for procurement teams: chemical identity is not the same as market authorization. Accordingly, a professional RFQ should specify the destination country and intended use. That enables the supplier to provide the most relevant documentation and prevents late-stage discoveries that the buyer needs an additional declaration, impurity panel or market-specific assessment. Compliance note: this article does not state that any orotic acid or orotate salt is automatically authorized for every food, supplement, pharmaceutical or therapeutic use. Buyers should evaluate the destination market, use level, regulatory category and finished-product requirements independently. A Better 2026 RFQ for Orotic Acid and Orotate Salts RFQ Field Weak Request Better Request Identity “Orotic acid” Exact form, CAS, hydrate state and target specification Quality “High purity” Assay method, water, elemental content, impurity limits and required certificates Quantity “Bulk” Sample quantity, validation batch, annual forecast and order size Application Not stated R&D / pharma intermediate / ingredient / other intended use Market Not stated Destination country and buyer's regulatory / customer-document checklist Supply Price only Lead time, packaging, shelf life, repeat supply, change notification and export documents FAQ: Procurement Questions Buyers Commonly Ask 1. What should a buyer verify first when sourcing orotic acid from China? Verify the exact chemical identity and hydration state before price. Orotic acid anhydrous is commonly identified as CAS 65-86-1, while the monohydrate is associated with CAS 50887-69-9. Confirm that the product name, CAS, formula, molecular weight and COA all describe the same form. 2. Is a lower assay limit always a sign of lower quality? Not necessarily. Assay must be interpreted together with hydrate state, water content, test method and intended application. A monohydrate and an anhydrous grade should not be compared on a mass basis without understanding the specification and analytical method. 3. What documents should professional buyers request? At minimum, request a current COA, specification/TDS and SDS. Depending on application and market, buyers may also need chromatograms, impurity or elemental data, residual-solvent information, microbiological data, origin statements, regulatory declarations and change-control commitments. 4. How can a buyer assess batch consistency before a long-term contract? Compare multiple recent COAs rather than one sample. Look for the trend and spread of assay, water, pH or other key parameters, ask whether the analytical method is fixed, and agree on notification rules for changes in manufacturing source, raw materials or test methods. 5. Are calcium, magnesium, zinc, potassium and lithium orotates interchangeable? No. They differ in cation, stoichiometry, hydration, molecular weight, elemental loading, solubility and intended use. They must be qualified as separate materials even though they share the orotate moiety. 6. What makes a sourcing partner useful beyond supplying a sample? For B2B buyers, value comes from correct grade matching, analytical-document support, communication across gram-to-commercial quantities, packaging coordination, export documentation and stable re-supply. These factors reduce requalification work and sourcing risk. Sources & Verification Notes NIST Chemistry WebBook. Orotic acid CAS 65-86-1; NIST also notes 50887-69-9 as the hydrate. NIST reference Tokyo Chemical Industry. Orotic Acid Monohydrate, CAS 50887-69-9. TCI reference FDA GSRS / UNII. Orotic acid substance identity; UNII availability does not imply regulatory approval. FDA substance record Polis Biotech public product and custom-synthesis pages. Used for current product links, published specifications and available analytical-service descriptions. Request a Quote, Sample or Technical Review When contacting Polis Biotech, include the exact product, intended market, application, target specification, annual demand and any analytical or documentation requirements. This helps the team match the correct grade before quotation and sample qualification. Nanchang Polis Biotech Co., Ltd. Email: sales@polisbiotech.com Tel: +86-791-88172690 · Mobile / WeChat: +86-13870623110 Web: www.polisbiotech.com

Recent research suggests that a lithium deficiency in the brain may be the primary cause of Alzheimer's disease. A team from Harvard University discovered that beta-amyloid proteins reduce lithium concentration, weakening its neuroprotective effects; however, lithium orotate can prevent this phenomenon and reverse memory degradation in mouse experiments. These findings, published in Nature, may in the future enable early dementia screening through lithium concentration testing and the development of novel treatment strategies using lithium orotate. Lithium deficiency in the brain may be the main cause of Alzheimer's disease. Lithium, the lightest metal and also the lightest solid element, was once added to soda to uplift people's mood upon consumption, and has been formulated into medications for treating manic-depressive disorder and depression. However, its most well-known application is undoubtedly in lithium batteries. A recent study has discovered that this versatile metal has another potential function: treating Alzheimer's disease. Alzheimer's disease, also known as dementia, is a slowly progressing neurodegenerative disease that worsens over time, affecting approximately 400 million people worldwide. With the global trend of aging population, this number will continue to rise, making it a healthcare issue that cannot be ignored. The main symptom of Alzheimer's disease is memory loss, but what is the initial trigger? Why do some people with similar brain changes gradually lose their memory while others do not? This question has puzzled neuroscientists for decades. Now, a group of scientists from Harvard University in the United States may have found the answer: a lack of lithium in the brain. This symbol typically doesn't require translation as it is often used to indicate a break, a division, or is part of a specific format in both Chinese and English. If it's meant to be a placeholder or has specific context, additional information would be needed for an accurate translation. In this case, since no context is provided, the symbol remains untranslated. Existing Alzheimer's disease treatments can only delay, not reverse, the condition. This paper, published in the journal *Nature* on August 6, 2025, confirms for the first time that this naturally occurring metal in the brain can protect it from neurodegeneration and maintain the normal functioning of all major brain cells. This significant research finding has reorganized our decades-long observations of Alzheimer's disease, providing a new theoretical foundation for the disease and offering brand-new strategies for early diagnosis, prevention, and treatment. Perhaps in the near future, by routinely drawing blood to test the brain lithium levels, we can identify early on individuals who belong to the potentially high-risk group for Alzheimer's disease, enabling early prevention and treatment. Recent studies have shown that Alzheimer's disease involves a series of brain abnormalities, such as the aggregation of beta-amyloid proteins, neurofibrillary tangles of tau proteins, and the deficiency of a protective protein named REST; however, these abnormalities do not fully explain the etiology of the disease. For instance, some individuals detected with the aforementioned abnormalities do not exhibit signs of cognitive decline; moreover, treatments recently developed targeting beta-amyloid proteins generally cannot reverse memory loss but only slightly slow down the rate of cognitive decline. From these phenomena, it is not hard to see that genetics and environment can influence the risk of developing Alzheimer's disease, yet scientists still do not understand why some individuals with risk factors develop the disease while others do not.   Lithium orotate shows hope of reversing Alzheimer's disease in mice Bruce Yankner, the corresponding author of this paper and a professor of genetics and neurology at the Blavatnik Institute at Harvard Medical School, said that lithium might be the crucial missing link. He believes that a lack of sufficient lithium in the brain may be the cause of Alzheimer's disease, which is a very novel viewpoint and also outlines a completely different treatment approach. He said that this research has kindled our hope that perhaps one day scientists could comprehensively treat this disease with drugs containing lithium, rather than just focusing on single aspects such us the original text seems incomplete here A research team from Harvard University discovered in human and mouse models that when beta-amyloid begins to form deposits in the early stages of Alzheimer's disease, it binds to lithium, reducing lithium concentration and thereby diminishing lithium's neuroprotective function in the brain, triggering symptoms such as memory loss. They simultaneously discovered that lithium orotate, a lithium compound, does not bind to beta-amyloid protein. Using lithium orotate to treat mice can reverse the progression of Alzheimer's disease, prevent brain cell damage, and restore memory. Bruce Yankner stated that one of their most exciting findings was that even extremely low doses of lithium orotate could produce significant effects.

Our objective: To sell amino acids products of ourselves and our partners globally and establish a "Made-in-China" image of amino acids.   R & D capability: We have established long-term cooperative relationships with renowned research institutes and universities, and gathered numerous senior engineers, professors and other top-notch talents to work with us.   Regular amino acid products are produced as per AJI, USP, EP, FCC standards, and can be customized to meet the specific needs of our clients.   To our partners: With years of great efforts, we have built long-term, stable and reliable business ?cooperation with various high quality companies and research institutes home and abroad. While achieving god corporate image, we have won the trust and support of a batch of clients with high loyalty and great potential for cooperation.